This document is a USPTO patent application (US20260083728A1) for compounds and pharmaceutical compositions useful in treating infections caused by parasitic protozoa, such as Leishmania or Trypanosoma. The application describes compounds of Formula I and Formula II and their pharmaceutically acceptable salts or derivatives. The filing date was September 18, 2023.

As this is a patent application, it does not impose direct compliance obligations on regulated entities. However, it signals potential future developments in treatments for parasitic protozoal infections, which may be of interest to pharmaceutical companies and researchers in the field. No immediate actions or deadlines are associated with this publication.